- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00734305
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115-6084
- Dana-Farber Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Fox Chase Cancer Center
-
-
Tennessee
-
Nashville,, Tennessee, Vereinigte Staaten, 37232
- The Vanderbilt-Ingram Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following standard therapy, or that have not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
- Patients must be > 18 years of age
- Patients or their legal representatives must be able to understand and sign an informed consent form
Patients must have evaluable or measurable tumor(s)
- Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy.
- Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121 (an effective form of contraception is an oral contraceptive or a double barrier method)
In addition, patients to be enrolled the Expansion Cohort must have/be:
- Advanced/metastatic breast cancer with histological/cytological documentation of ER-, PR-, Her2/neu non-over-expressing breast cancer (triple negative breast cancer); OR,
- Patients must have advanced/metastatic breast cancer with histologically or cytologically confirmed ER+ and/or PR+, Her2/neu non-over-expxressing OR,
- Patients must have advanced/metastatic histological confirmation of epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; OR,
- Additional tumor types such as metastatic colorectal, advanced non small cell lung cancer, and others may be considered on a per-patient basis
- Tumor tissue amenable to biopsy
- Platelet counts, partial thromboplastin time (PTT) and international normalized ratio (INR) within normal limits.
- Willing to undergo tumor biopsy twice (once before and once after treatment with MM-121)
- Blocks of archived formalin-fixed, paraffin-embedded, unstained tumor tissue available for submission. Patients with no available archived tumor tissue available must receive Sponsor approval prior to enrollment.
Exclusion Criteria:
- Patients for whom potentially curative antineoplastic therapy is available
- Patients who are pregnant or lactating
- Patients with an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)
- Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic); patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial
- NYHA Class III or IV congestive heart failure or LVEF < 55%
- Known HIV, hepatitis B or C (active, previously treated or both)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Dose Escalation
Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
|
Dose escalation Frequency - once weekly
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Objective Response Rate and Duration
Zeitfenster: Time from first dose to date of progression, with a median of 7.1 weeks
|
To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response is defined as a >20% decrease in tumor burden from baseline and a Complete Response is defined as complete disappearance of tumor burden from baseline. Duration of response is defined as the length of time in weeks from observation of response until progression. NOTE: because no patients experienced an objective response as shown below, duration of response is not presented. No duration of response could be measured. |
Time from first dose to date of progression, with a median of 7.1 weeks
|
Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities
Zeitfenster: From date of first dose to 30 days after termination, the longest 47 weeks
|
Using a 3+3 dose escalation model, the maximum tolerated dose was determined by assessing dose-limiting toxicities in each cohort from cohort 1-6.
Cohort 1 began at 3.2 mg/kg IV QW and the dose escalated in separate cohorts from 6 mg/kg IV QW, 10 mg/kg IV QW, 15 mg/kg IV QW, 20 mg/kg IV QW, to the highest scheduled testing dose at 40 mg/kg one-time loading dose on cycle 1, week 1 followed by 20 mg/kg IV QW maintenance doses.
If 3 patients were treated and passed the observation window, escalation to the next cohort was initiated.
If a DLT was reported, 3-4 additional patients were enrolled and observed.
If a DLT was observed in the expanded cohort, this dose was considered to be the maximum tolerated dose.
The maximum tolerated dose was defined at the cohort in which two dose-limiting toxicities were observed, or as the highest target dose tested in the absence of DLTs.
The determined MTD was considered the Recommended Phase 2 Dose and was used to open the expansion cohort.
|
From date of first dose to 30 days after termination, the longest 47 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
To Describe the Dose-limiting Toxicity of MM-121 as a Monotherapy
Zeitfenster: From date of first dose to 30 days after termination, the longest 47 weeks
|
To establish the safety of escalating doses of MM-121 administered as a monotherapy in order to determine the recommended phase 2 dose.
Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose.
Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD to be used for the expansion cohort.
DLTs were not measured in the Expansion Cohort.
|
From date of first dose to 30 days after termination, the longest 47 weeks
|
To Determine the Pharmacokinetic and Immunogenicity Parameters of MM-121
Zeitfenster: At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients
|
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first cycle of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. The maximum observed concentration (Cmax) is presented and was calculated usig Non-compartmental analysis (NCA). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (3.2 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 40/20 mg/kg). Immunogenicity data is not available. |
At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients
|
To Determine the Pharmacokinetic Parameters of MM-121
Zeitfenster: At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients
|
Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first cycle of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121.
The AUC is presented and was calculated usig Non-compartmental analysis (NCA).
Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA).
Data is presented per dose level of MM-121 (3.2 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 40/20 mg/kg).
|
At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Kwok Kin Wong, MD, Dana-Farber Cancer Institute
- Hauptermittler: Keedy L Vicki, MD, Vanderbilt University Medical Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MM-121-01-100
- MM-121
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fortgeschrittene solide Tumoren
-
Incyte CorporationBeendetMalignität eines soliden TumorsVereinigte Staaten, Frankreich, Vereinigtes Königreich, Italien, Korea, Republik von, Japan, Spanien, Israel, Dänemark, Deutschland, Schweiz
-
Martin GutierrezHackensack Meridian Health; Karyopharm Therapeutics IncZurückgezogen
-
National University of SingaporeCalifornia Table Grape CommissionNoch keine RekrutierungAltern | Makula; Degeneration | Advanced Glycation End-Produkte
-
Amsterdam UMC, location VUmcAbgeschlossenKnochenmetastasen eines bösartigen TumorsNiederlande
-
Extremity MedicalRekrutierungArthrose | Entzündliche Arthritis | Karpaltunnelsyndrom (CTS) | Posttraumatische Arthritis | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium und Trapezoid Advanced Collapse (STTAC) | Kienbock-Krankheit des Erwachsenen | Radiale Malunion | Ulnare Translokation und andere BedingungenVereinigte Staaten
-
Northwell HealthZurückgezogenDiabetes | SGLT-2-Inhibitoren | Advanced Glycation End-Produkte
-
Second Affiliated Hospital, School of Medicine,...RekrutierungLeptomeningeale Metastasierung eines soliden TumorsChina
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; Assign Data Management and Biostatistics GmbHAbgeschlossenNeuroendokrines Karzinom Grad 3 | Schlecht differenziertes malignes neuroendokrines Karzinom | Neuroendokrines Karzinom Grad 1 [Gut differenziertes neuroendokrines Karzinom], das auf G3 umgestellt wurde | Neuroendokrines Karzinom Grad 2 [mäßig differenziertes neuroendokrines Karzinom]... und andere BedingungenDeutschland
-
Century Therapeutics, Inc.RekrutierungHämatologische Malignität | Malignität eines soliden TumorsVereinigte Staaten
-
Töölö HospitalTurku University Hospital; Tampere University Hospital; Jyväskylä Central Hospital und andere MitarbeiterRekrutierungArthrose am Handgelenk | Scapholunate Advanced CollapseFinnland
Klinische Studien zur MM-121
-
SanofiMerrimack PharmaceuticalsAbgeschlossenSolider TumorkrebsVereinigte Staaten
-
Merrimack PharmaceuticalsBeendetDarmkrebs | Plattenepithelkarzinom des Kopfes und Halses | Nicht-kleinzelligem LungenkrebsVereinigte Staaten
-
Valeant PharmaceuticalsUnbekannt
-
REGENXBIO Inc.Aktiv, nicht rekrutierendMukopolysaccharidose Typ II (MPS II)Vereinigte Staaten, Brasilien
-
Valeant PharmaceuticalsUnbekannt
-
Kala Pharmaceuticals, Inc.AbgeschlossenSyndrome des trockenen Auges | Keratokonjunktivitis siccaVereinigte Staaten
-
Elevation OncologyMerrimack PharmaceuticalsBeendetAdenokarzinom | Nicht-kleinzelligem Lungenkrebs | NSCLC | HeregulinSpanien, Kanada, Vereinigte Staaten, Deutschland, Ungarn, Frankreich
-
Vertex Pharmaceuticals IncorporatedAktiv, nicht rekrutierendMukoviszidoseVereinigte Staaten, Australien, Deutschland, Schweden, Schweiz, Frankreich, Niederlande, Vereinigtes Königreich
-
Vertex Pharmaceuticals IncorporatedAktiv, nicht rekrutierendMukoviszidoseVereinigte Staaten, Spanien, Vereinigtes Königreich, Belgien, Niederlande, Dänemark, Israel, Neuseeland, Frankreich, Australien, Irland, Deutschland, Schweden, Kanada, Tschechien, Schweiz, Portugal, Italien, Österreich, Ungarn, ... und mehr
-
Kala Pharmaceuticals, Inc.AbgeschlossenAugeninfektionen, Reizungen und EntzündungenVereinigte Staaten